Published in J Skin Cancer on May 05, 2014
Economic burden of toxicities associated with treating metastatic melanoma in eight countries. Eur J Health Econ (2015) 0.84
Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma. Adv Ther (2016) 0.80
Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study. Cancer Med (2016) 0.77
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol (2000) 2.86
Accuracy of Medicare claims data for rheumatologic diagnoses in total hip replacement recipients. J Clin Epidemiol (2003) 2.72
Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol (2013) 2.71
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. Eur J Cancer (2012) 2.05
Misclassification and selection bias when identifying Alzheimer's disease solely from Medicare claims records. J Am Geriatr Soc (1999) 1.95
Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T (2012) 1.19
Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther (2012) 1.16
Temozolomide for the treatment of metastatic melanoma. Curr Oncol (2007) 1.13
Surgery for distant melanoma metastasis. Cancer J (2012) 1.03
Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Clin Cancer Res (2001) 0.88